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Severe acute respiratory syndrome coronavirus 2
antibodies in pregnant women admitted to labor
and delivery units
OBJECTIVE:
Serologic testing for severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G
(IgG) antibodies is now broadly available in the United States.
The SARS-CoV-2 antibody levels rise within 2 to 3 weeks
after infection and can indicate whether an individual has
ever been infected, irrespective of symptomatic or
asymptomatic presentation. Serology is not recommended
by the Centers for Disease Control and Prevention as a
diagnostic test for an active infection but instead can be
used to understand the epidemiology of the virus and
identify the groups who are at a higher risk of infection.1
Previous studies utilizing polymerase chain reaction (PCR)
tests to detect SARS-CoV-2 from nasopharyngeal swabs for
disease conﬁrmation suggest that pregnancy does not seem to
increase the risk of acquiring a SARS-CoV-2 infection when
compared with the nonpregnant population.2 However, PCR
testing at the time of hospitalization for delivery may underestimate the prevalence of SARS-CoV-2 in pregnancy;
infection during an earlier gestational period may only be
detectable by antibody testing. Other factors that may affect
the prevalence of SARS-CoV-2 infection in pregnancy include
the viral prevalence in different regions of the country,
asymptomatic carriage of the virus, unavailability of testing in
particular regions of the country, and whether the patient
seeks screening for various indications (eg, screening offered
through employment, the presence of symptoms, and
protocol-driven routine screening in labor and delivery
[L&D] units).
The objective of this study was to determine the seroprevalence rate of SARS-CoV-2 antibodies in pregnant women
admitted to L&D units. A secondary objective was to correlate
the serum antibody status to the results of the PCR tests to
determine the prevalence of potential immunity in our
population.

A total of 7 hospitals with L&D units in the
Northwell Health system in New York State were included in
this study. The participants were all women admitted to the
L&D units between May 27, 2020, and July 24, 2020, who had
their blood drawn for SARS-CoV-2 IgG antibody testing. IgG
titers were classiﬁed as either positive, negative, or equivocal.
The serology test used in this study was the Roche Elecsys
Anti-SARS-CoV-2 (Roche Diagnostics International Ltd,
Rotkreuz, Switzerland) test. This test has a false positive
rate of 0.2%, secondary to cross reactivity with the
cytomegalovirus, Epstein-Barr virus, and systemic lupus
erythematosus. The false negative rate for the test is
unknown.3 False negative results may be because of testing
before seroconversion or after the waning of antibody levels
over time. We used a universal testing approach for SARSCoV-2 on admission to an L&D unit with a PCR test of a
nasopharyngeal swab. The PCR test results were recorded
for all study participants, if available.
This study received institutional review board approval from
the Feinstein Institutes for Medical Research at Northwell
Health. Descriptive statistics were used to evaluate the data.

STUDY DESIGN:

During the study period, 1671 women delivered
in the Northwell Health system and had available SARS-CoV-2
antibody results. Of those, 269 were seropositive (16.1%), 1400
were seronegative (83.7%), and 2 were equivocal (0.11%). The
PCR results for each group are presented in Table 1.

RESULTS:

To date, 3 other studies have examined the
seroprevalence of SARS-CoV-2 antibodies in pregnancy with
prevalence rates between 0.6% and 10.1% (Table 2).4e6 In
our cohort, 16.1% of pregnant women were seropositive for
SARS-CoV-2 antibodies, which is the highest reported
prevalence rate of SARS-CoV-2 in pregnancy. This likely

CONCLUSION:

TABLE 1

COVID-19 antibody and PCR results for pregnant women admitted to L&D units
PCR result
Positive, n (%)

Negative, n (%)

Not available, n (%)

Antibody status
Positive (16.1%; n¼269)

51 (19)

217 (80.6)

1 (0.4)

Negative (83.7%; n¼1400)

15 (1.0)

1372 (98.0)

13 (1.0)

Equivocal (0.11%; n¼2)

0

2 (100)

0

COVID-19, coronavirus disease 2019; L&D, labor and delivery; PCR, polymerase chain reaction.
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reﬂects the higher prevalence of the virus in New York State,7
which was once the epicenter of SARS-CoV-2 infections in
the United States.
The results from both the SARS-CoV-2 PCR and antibody tests can help to determine the timing of infection.
An acute infection may be characterized by a positive PCR
and negative antibody test result. A past infection may be
characterized by a negative PCR and positive antibody test
result. If both tests are positive, a recent or past infection
may have occurred. The PCR test results for some individuals have been reported to remain positive for weeks
after infection.8 There is a concern that some patients
who were exposed to the virus have a transient elevation
in antibody levels, complicating the interpretation of the
test results.
Universal testing in L&D units represents a unique opportunity to continuously study the exposure to SARS-CoV-2
in a population. The general public has been practicing social
distancing and avoiding healthcare contact, creating a selection bias in seroprevalence studies. Pregnant women, a
generally healthy and mostly asymptomatic group, continue
to receive routine prenatal and L&D services. A cohort of
pregnant women admitted to L&D units is therefore more
representative of the general population.
It is still unclear whether SARS-CoV-2 antibodies confer
immunity to reinfection and for how long. However, there is
growing interest in the literature on SARS-CoV-2 antibodies.
Antibody testing may be a useful tool for studying exposure
rates to the virus in different populations, developing a vaccine, and in treating sick patients with convalescent plasma.
Further research is necessary to determine the antibody
response to SARS-CoV-2 in pregnant women, its accuracy,
and its role in the management of seropositive pregnant
women and their fetuses.
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New York City and Long
Island, NY, USA
May 27, 2020, to July 24, 2020
Delivery admission
1671
Current study

10.1
Turin, Piedmont, Italy
April 16, 2020, to June 4, 2020
First trimester
138
Cosma et al, 2020

0.6
Jena, Thuringia, Germany
April 6, 2020, to May 13, 2020
Delivery admission
234

6

Zöllkau et al,5 2020

6.2
Philadelphia, PA, USA
April 4, 2020, to June 3, 2020
Antepartum and
delivery admission
1293
Flannery et al, 2020

Study period
First author, year

4

Location
Timing during
pregnancy

Seroprevalence studies of SARS-CoV-2 antibodies in pregnancy

TABLE 2
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Sample
size (N)

Positive seroprevalence
results for SARS-CoV-2
antibodies (%)
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